MedPath

Triptorelin

Generic Name
Triptorelin
Brand Names
Decapeptyl, Trelstar, Triptodur
Drug Type
Small Molecule
Chemical Formula
C64H82N18O13
CAS Number
57773-63-4
Unique Ingredient Identifier
9081Y98W2V
Background

Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Indication

Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Associated Conditions
Advanced Prostate Cancer
Associated Therapies
Controlled ovarian hyperstimulation therapy
Clinical Trials
Related News

Comparison of Triggers in Double Ovarian Stimulation (DuoStim).

First Posted Date
2022-04-11
Last Posted Date
2022-04-11
Lead Sponsor
Instituto Bernabeu
Target Recruit Count
165
Registration Number
NCT05321511
Locations
🇪🇸

Instituto Bernabeu, Madrid, Spain

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Phase 2
Recruiting
Conditions
Prostate Cancer
Interventions
Procedure: Local treatment for primary lesion
Radiation: Radiotherapy for primary lesion
Radiation: Radiotherapy for metastatic lesion
First Posted Date
2022-01-28
Last Posted Date
2022-03-16
Lead Sponsor
Fudan University
Target Recruit Count
160
Registration Number
NCT05212857
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Long-term Use of Mifepristone in the Treatment of Adenomyosis

Early Phase 1
Conditions
Adenomyosis
Mifepristone
Interventions
First Posted Date
2021-12-09
Last Posted Date
2021-12-09
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Target Recruit Count
140
Registration Number
NCT05151016
Locations
🇨🇳

Women's Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China

Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles

First Posted Date
2021-11-09
Last Posted Date
2021-11-09
Lead Sponsor
Mansoura University
Target Recruit Count
200
Registration Number
NCT05112692

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

First Posted Date
2021-09-20
Last Posted Date
2025-05-09
Lead Sponsor
NRG Oncology
Target Recruit Count
2050
Registration Number
NCT05050084
Locations
🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States

and more 556 locations

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Phase 3
Completed
Conditions
Central Precocious Puberty
Interventions
First Posted Date
2021-08-31
Last Posted Date
2025-02-19
Lead Sponsor
Ipsen
Target Recruit Count
66
Registration Number
NCT05029622
Locations
🇨🇳

Children's Hospital of Fudan University, Changhai, China

🇨🇳

Pingxiang Maternity and Child Care, Pingxiang, China

🇨🇳

Chengdu Women's & Children's Central Hospital, Chengdu, China

and more 11 locations

SRT Versus SRT+ADT in Prostate Cancer

Phase 3
Recruiting
Conditions
Prostate Cancer
Interventions
First Posted Date
2021-08-25
Last Posted Date
2023-04-18
Lead Sponsor
Marco Lorenzo Bonu
Target Recruit Count
310
Registration Number
NCT05019846
Locations
🇮🇹

ASST Spedali Civili of Brescia, Brescia, BS, Italy

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Interventions
First Posted Date
2021-05-03
Last Posted Date
2022-12-29
Lead Sponsor
Hongqian Guo
Target Recruit Count
75
Registration Number
NCT04869371
Locations
🇨🇳

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Agonist Trigger With HCG Luteal Supplementation vs HCG Trigger With Progesterone Luteal Supplementation in Antagonist Controlled HyperstimulationCycle

Not Applicable
Completed
Conditions
Infertility, Female
Interventions
First Posted Date
2021-04-15
Last Posted Date
2021-11-18
Lead Sponsor
Ain Shams University
Target Recruit Count
100
Registration Number
NCT04846218
Locations
🇪🇬

AinShams Maternity Hospital, Cairo, Egypt

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Phase 2
Recruiting
Conditions
Recurrent Prostate Cancer
Prostate Cancer
Oligometastasis
Oligorecurrence
De Novo Prostate Cancer
Metastatic Prostate Cancer
Interventions
Procedure: PET-directed Local Therapy using Surgery
Radiation: PET-directed Local Therapy using Radiation
Other: Salvage Local Therapy for locally recurrent disease
Radiation: Prostate-directed Radiation for De novo oligometastatic prostate cancer
First Posted Date
2021-03-09
Last Posted Date
2025-01-07
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
464
Registration Number
NCT04787744
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States

🇺🇸

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States

🇺🇸

Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States

and more 16 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy